Global X Telemedicine & Digital Health ETF

HIMS Options Market Volume and Open Interest Data

Novo Nordisk and Hims & Hers Reach Settlement and Channel Partnership for GLP-1 Drugs

Hims & Hers Health announces proposed A$1.64 billion acquisition of digital health company Eucalyptus

Clear Street Group Inc. Invests $87.37 Million in Hims & Hers Health, Inc.

Hims & Hers to sell branded weight-loss drugs after reaching a lawsuit settlement with Novo Nordisk

Veeva Systems Acquires Ostro to Enhance AI-Driven Interactions

Hims & Hers grants 526,711 RSUs to Chief Policy Officer

Hims Announces Sale of Branded Weight-Loss Drugs, Sparking a Surge in Options Market Trading Volume

Hims shares set for best week on record after new Novo Nordisk deal

Analysts' Consensus Rating for Hims & Hers Health is "Hold"

Institutional Investor Discloses New Investment in Hims & Hers Health

Zacks Lists Hims & Hers Health as a New 'Strong Sell' Stock

Insulet Recalls Certain Omnipod 5 Pods

Hims & Hers announced a plan to acquire the international digital health company Eucalyptus for up to $1.15 billion.

Analysts note Hims & Hers faces cost and regulatory risks despite recent stock surge

First Shanghai Initiates Buy Rating on Hims & Hers Health with a $31.1 Price Target

MEXC to List HIMS USDT-M Stock Futures on March 12

Cathie Wood's ARK Invest increased its stake in Tempus AI.

Hims & Hers Health stock soars, up 72% in 3 trading days, following partnership agreement with Novo Nordisk

Barclays raises price target for Hims & Hers to $29

bioAffinity Tech

Firefly Neuroscience

Silvaco

eLong Power

T-REX 2X Long UPXI Daily Target ETF

Polaryx Therapeutics

TCW Strategic Income Fund, Inc.

Stak

iSpecimen

Oruka Therapeutics

EDOC

HEAL

FDHT

TDOC

SBIO

Labcorp Holdings Inc. (LH) shares fell 2.78% to $262.91 on a poor trading day, while the S&P 500 and Dow Jones also declined. Despite this, Labcorp's performance was better than some competitors, with IQVIA down 5.04%, Centene down 3.60%, and Teladoc down 2.01%. Labcorp remains 10.49% below its 52-week high of $293.72 reached on October 21st. Trading volume was 734,820, surpassing the 50-day average of 715,209.

Dow Jones

Centene

VanEck Biotech ETF

Global X HealthTech ETF

IQVIA

Fidelity Digital Health ETF

SPDR S&P Biotech

Labcorp

Proshares Ultra Nasdaq Biotech

Teladoc

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares Biotechnology ETF

Labcorp Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day

Teladoc Health shares are trading higher after Deutsche Bank upgraded the stock from Hold to Buy rating and announced a $11 price target.

benzinga_article

Teladoc Health's stock surged after reporting better-than-expected quarterly results, with a loss of 14 cents per share against an anticipated 18 cents loss, and sales of $642.27 million exceeding expectations. However, the company provided cautious guidance for 2026, predicting a loss of 70 cents to $1.10 and sales between $2.47 billion and $2.59 billion. Analysts have mixed views, with Deutsche Bank upgrading the stock to Buy, while others like BTIG and Citigroup remain cautious, lowering price targets. Currently, TDOC is trading at $5.59, showing short-term strength but long-term struggles.

Teladoc Health Stock Pops - Here's Why

Deutsche Bank Aktiengesellschaft upgraded Teladoc Health (NYSE:TDOC) from a "hold" to a "buy" rating, setting a price target of $11.00, indicating a potential upside of 107.35%. Other analysts have varied opinions, with Oppenheimer lowering their target to $7.00 and Canaccord Genuity to $10.00. Currently, Teladoc has a consensus rating of "Hold" with a target of $7.76. The stock opened at $5.31, with a market cap of $946.41 million and a recent quarterly EPS of ($0.14), exceeding estimates. CEO Charles Divita III sold shares, reducing his stake by 7.86%.

Market Beat

Teladoc Health (NYSE:TDOC) Upgraded at Deutsche Bank Aktiengesellschaft

The global telehealth market is projected to exceed USD 2 trillion by 2034, driven by the rise in chronic diseases and the adoption of digital health technologies. Key factors include improved access to healthcare, government support, and the demand for convenient care. North America leads the market, followed by Europe and Asia-Pacific, with significant contributions from major companies like Teladoc and Siemens Healthineers. The market is expected to grow at a rate of approximately 32% from 2025 to 2032, reaching around USD 210 billion by 2025.

prnewswire

Siemens Healthineers AG

17:46 ETGlobal Telehealth Market is Projected to Cross the USD 2 Trillion Mark by 2034, Driven by Digital Healthcare Transformation | DelveInsight

Labcorp Holdings Inc. (LH) shares rose 1.46% to $273.61 on Monday, ending a five-day losing streak, while the S&P 500 and Dow Jones also gained. However, Labcorp's performance lagged behind competitors like IQVIA Holdings, which rose 2.33%, and Teladoc Health, which increased by 4.33%. Labcorp remains 6.85% below its 52-week high of $293.72 reached on October 21st, with trading volume at 563,045, below the 50-day average of 710,432.

Labcorp Holdings Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

ARVR

Teladoc Health Inc's short interest has increased by 9.38%, with 30.57 million shares sold short, representing 19.25% of available shares. It would take traders an average of 3.86 days to cover these positions. An increase in short interest indicates a bearish sentiment among investors. Compared to its peers, Teladoc's short interest is higher, with an average of 7.77% for similar companies. This data suggests that while short selling is on the rise, it does not necessarily predict a near-term decline in stock price.

First Trust Indxx Metaverse ETF

How Do Investors Really Feel About Teladoc Health Inc?

Labcorp Holdings Inc. (LH) shares rose 1.71% to $287.62 on Thursday, but underperformed compared to competitors like IQVIA Holdings Inc. (+5.39%), Centene Corp. (+0.56%), and Teladoc Health Inc. (+15.05%). The stock remains 2.08% below its 52-week high of $293.72 reached on October 21st. Trading volume was 594,665, which is below the 50-day average of 750,125.

Labcorp Holdings Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

Teladoc Health (NYSE:TDOC) has been analyzed by 8 analysts, revealing mixed sentiments with an average 12-month price target of $6.81, down from $8.86. Recent ratings show a trend of downgrades across various firms, with notable reductions in price targets. The company faces challenges with a -2.2% revenue growth and a net margin of -7.9%. Despite a strong return on equity of -3.52%, its debt-to-equity ratio of 0.75 indicates significant debt levels. Analyst ratings are crucial for investors, reflecting expert evaluations of the company's performance and market position.

Demystifying Teladoc Health: Insights From 8 Analyst Reviews

Teladoc Health's stock surged 13.44% to $5.28 after beating earnings estimates, reporting a quarterly loss of 14 cents per share against a consensus loss of 18 cents. Revenue rose to $642.27 million, surpassing expectations. Despite mixed market performance, Teladoc's growth is attributed to company-specific factors. However, 2026 guidance indicates a projected loss of 70 cents to $1.10 per share, with sales between $2.47 billion and $2.59 billion, below consensus estimates. Analysts maintain a Hold rating with a price target averaging $9.26, reflecting cautious optimism amid bearish technical indicators.

What's Driving Teladoc Health's Rally?

Reuters

Teladoc Health Q4 revenue beats expectations

Teladoc Health (NYSE:TDOC) reported Q4 earnings on February 25, 2026, beating estimates by 33.33% with an EPS of $-0.14 compared to an estimate of $-0.21. Revenue increased by $1.78 million year-over-year. The company also provided Q1 2026 guidance, expecting earnings between $-0.45 and $-0.35 per share. Previous performance showed a consistent trend of beating EPS estimates, impacting share prices positively. For more details, visit their earnings calendar.

Teladoc Health Q4 Earnings Summary & Key Takeaways

2627

2637

2638

2626

CTEC

EBIZ

Global X ETFs ICAV announced the unaudited net asset values (NAV) for various UCITS ETFs as of February 23, 2026. Key NAVs include: Video Games & Esports Acc Class at 13.1777, Telemedicine & Digital Health Acc Class at 8.2033, CleanTech Acc Class at 8.8797, E-Commerce Acc Class at 13.2584, and Robotics & AI Acc Class at 25.4182. Other notable NAVs include U.S. Infrastructure Developments Acc Class at 51.2493 and Lithium & Battery Tech Acc Class at 13.1399. All values reflect income with debt at fair value.

London Stock Exchange

Global X Japan Co., Ltd.

Global X CleanTech ETF

Global X E-commerce ETF

REG - Mirae Asset ETF ICAV - Global X ETF ICAV 23.02.26

HIMZ

Hims & Hers Health (NYSE:HIMS) reported its Q4 earnings on February 23, 2026, beating estimates with an EPS of $0.08 compared to the expected $0.03, marking a 166.67% increase. Revenue rose to $136.68 million year-over-year. In the previous quarter, the company missed EPS estimates, resulting in a 3.6% drop in share price. Historical performance shows fluctuations in EPS and revenue across recent quarters.

Defiance Daily Target 2X Long HIMS ETF

iShares US Medical Devices

VG Health

iShares Global Healthcare

iShares US Healthcare Providers

SPDR S&P Health

SPDR S&P Health Equip

Defiance Leveraged Long +Income HIMS ETF

Health Care Select Sector SPDR

Hims & Hers Health

Hims & Hers Health: Q4 Earnings Insights

HERO

512170

Global X ETFs ICAV has announced the unaudited net asset values (NAV) for various UCITS ETFs as of February 20, 2026. The NAV per share for the USD Acc Class and Dist Class of several funds are as follows: Video Games & Esports: 13.1877 (Acc), 12.9309 (Dist); Telemedicine & Digital Health: 8.2236 (Acc), 7.9036 (Dist); CleanTech: 8.9067; E-Commerce: 13.6608; Data Center REITS: 23.0693; Autonomous & Electric Vehicles: 16.3878 (Acc), 15.7363 (Dist); Cybersecurity: 11.3265; Robotics & AI: 25.6336 (Acc), 25.4427 (Dist); Fintech: 7.468 (Acc), 7.4408 (Dist); Genomics & Biotechnology: 8.3724; U.S. Infrastructure: 52.0058 (Acc), 50.9257 (Dist); Lithium & Battery Tech: 13.0344; Internet of Things: NAV not fully provided.

Global X Telemedicine & Digital Health ETF(EDOC.US)

Labcorp Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day

Teladoc Health shares are trading higher after Deutsche Bank upgraded the stock from Hold to Buy rating and announced a $11 price target.

Teladoc Health Stock Pops - Here's Why

Teladoc Health (NYSE:TDOC) Upgraded at Deutsche Bank Aktiengesellschaft

17:46 ETGlobal Telehealth Market is Projected to Cross the USD 2 Trillion Mark by 2034, Driven by Digital Healthcare Transformation | DelveInsight